Welcome to our dedicated page for SpyGlass Pharma news (Ticker: SGP), a resource for investors and traders seeking the latest updates and insights on SpyGlass Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SpyGlass Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SpyGlass Pharma's position in the market.
SpyGlass Pharma (Nasdaq: SGP) priced an initial public offering of 9,375,000 shares at $16.00 per share, generating approximately $150 million in gross proceeds before underwriting discounts and expenses. The company granted underwriters a 30-day option for an additional 1,406,250 shares.
SpyGlass Pharma common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, with the offering expected to close on February 9, 2026, subject to customary closing conditions. The registration statement became effective January 30, 2026.
FAQ
What is the current stock price of SpyGlass Pharma (SGP)?
